+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

  • ID: 4564554
  • Report
  • May 2018
  • Region: Global
  • 546 Pages
  • La Merie Publishing
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets which are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.

This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.

The original reports were published in January and May 2018, respectively:

`Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends`

and

`TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals`

*Detailed report descriptions, tables of contents and sample pages from the reports can be found on the respective product pages, which can be found in the `Also available` Section below.
Note: Product cover images may vary from those shown
Adroll
adroll